Amgen’s Growth Story Relies Mainly On Continuing Plot Lines
Forecasts Mid-Single-Digit Revenue CAGR Through 2030
Executive Summary
Established brands Repatha and Otezla, new launches Lumakras and Tezspire, and the Amjevita-led biosimilars portfolio will provide most of the company’s growth through the end of this decade.
You may also be interested in...
Amgen Expands R&D C-Suite As Reese Focuses On Technology, Bradner Leads R&D
Amgen appointed R&D head David Reese as EVP and chief technology officer and recruited former Novartis executive Jay Bradner as EVP of R&D and chief scientific officer.
Verve Hits The Clinic With Gene-Edited Cholesterol-Lowering Drug
The company dosed the first patient in its study of base editor VERVE-101, a possible single-dose treatment for HeFH that joins a growing list of PCSK9-targeted therapy candidates.
Supreme Court May Consider Ruling Invalidating Amgen’s Repatha Patents
Court asks Solicitor General to weigh in on petition challenging Federal Circuit’s standard for determining patent enablement in Amgen’s dispute with PCSK9 inhibitor rivals Sanofi and Regeneron. GlaxoSmithKline, Biogen, Bristol-Myers Squibb, and Merck filed briefs in support of Amgen.